Difference between revisions of "Team:EPFL"
| Line 40: | Line 40: | ||
<div class="col-lg-12"> | <div class="col-lg-12"> | ||
<div class="pr-md-4"> | <div class="pr-md-4"> | ||
| − | <h3 class="heading h3 text-white text-center">What is CAPOEIRA ?</h2> | + | <h3 class="heading h3 text-white text-center"><font size="+2">What is CAPOEIRA ?</font></h2> |
| − | <p class="lead text-white my-4">While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project | + | <p class="lead text-white my-4"><font size="+2">While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project |
“CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. | “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. | ||
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments | First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments | ||
presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential | presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential | ||
relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back! | relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back! | ||
| − | + | </font> | |
</p> | </p> | ||
</div> | </div> | ||
| Line 71: | Line 71: | ||
<div class="row row-grid align-items-center slice slice-lg"> | <div class="row row-grid align-items-center slice slice-lg"> | ||
<div class="col-lg-5"> | <div class="col-lg-5"> | ||
| + | <div class="animate-this"> | ||
<img src="https://static.igem.org/mediawiki/2018/0/01/T--EPFL--bioinfo.svg" class="img-center img-fluid" width="300px"> | <img src="https://static.igem.org/mediawiki/2018/0/01/T--EPFL--bioinfo.svg" class="img-center img-fluid" width="300px"> | ||
| + | </div> | ||
</div> | </div> | ||
<div class="col-lg-7 ml-lg-auto"> | <div class="col-lg-7 ml-lg-auto"> | ||
| Line 90: | Line 92: | ||
<div class="col-lg-7 order-lg-1"> | <div class="col-lg-7 order-lg-1"> | ||
<div class="pr-lg-7"> | <div class="pr-lg-7"> | ||
| − | <h2 class="text-center">Vaccine</h2> | + | <h2 class="text-center"><font size="+2">Vaccine</font></h2> |
<p class="lead text-gray my-4 text-center"> | <p class="lead text-gray my-4 text-center"> | ||
<font size="+2">Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes</font> | <font size="+2">Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes</font> | ||
Revision as of 18:47, 17 October 2018
CAPOEIRA
Cancer Personalized Encapsulin Immunotherapy and Relapse Assay
Learn more about our project
What is CAPOEIRA ?
While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
This is CAPOEIRA
Bioinformatics
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells
Vaccine
Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes
Dendritic cell Activation
This encapsulin vaccine activates dendritic cells which trigger T-cell's attack on the neoantigen bearing cancer cells
Follow-up
Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA